Friedman Kaplan recently filed an amicus brief on behalf of a coalition of distinguished legal scholars in Smith & Wesson Brands., et. al. vs. Estados Unidos Mexicanos, the first case in which the U.S. Supreme Court will consider the scope of a federal law that provides broad – but not absolute – immunity to gun manufacturers and sellers whose products are used to commit acts of violence. More

Friedman Kaplan mourns the loss of our partner Larry Robbins, who passed away on November 2, 2024. He was 72. More

Friedman Kaplan is pleased to announce that it has achieved Mansfield Certification Plus for 2023–24. Mansfield is a year-long, structured certification process through Diversity Lab that the firm has committed to since 2022. Named for the first woman admitted to practice law in the United States, Mansfield’s accreditation process takes a behavioral science approach that embeds accountability, transparency, and knowledge sharing into talent practices, with the focus on opening the door wider and ensuring that opportunities for advancement are transparent and inclusive. More

Friedman Kaplan again has been named a Compass Award winner by the Leadership Council on Legal Diversity (LCLD), which recognizes law firms and corporations that show a strong commitment to building a more inclusive legal profession. More

The New York Law Journal recently published an article written by Friedman Kaplan counsel Bonnie M. Baker regarding a potential amendment to New York State’s criminal “revenge porn” statute after a recent New York Criminal Court decision from Kings County. More

The New York Law Journal recently published an article written by Friedman Kaplan counsel Bonnie M. Baker on the U.S. Supreme Court’s decision in Diaz v. United States, regarding expert testimony on a criminal defendant’s mental state and how defense counsel can navigate the post-Diaz landscape.  More

Law360 has published an “Expert Analysis” article, co-authored by Friedman Kaplan litigation counsel Elizabeth Bierut and associate Angie Garcia, offering practical guidance to drug manufacturers on how to comply with New York’s recently enacted drug pricing transparency law. More